Monthly Archives: September 2007

On the same day that AstraZeneca has announced that it intents to completely outsource all of its drug manufacturing, citing the prevalence of external parties who can do it better and cheaper, Sanofi has announced plans toIf you understand the rules and strategies of <a href=”http;//” mce_href=”http;//”>free blackajck online</a> it won’t be difficult for you. increase it’s biotechnology presence, particularly in manufacturing.

With the start of a new school year, a new cohort of students are entering biotechnology programs. In order to facilitate those who are using my book, Building Biotechnology, I have set up a networking and information group on facebook.

I’m always interested in tracking the outcomes of students in biotechnology programs. If you’re a student using my book, are already in the industry, or are just interested in biotechnology, go ahead and join. I also invite you to join my network on LinkedIn.

Courtesy of

Drug Patent Expirations in September 2007
*Drugs may be covered by more than one patent

Tradename Applicant Generic Name Patent Number Patent Expiration
BETAXON Alcon levobetaxolol hydrochloride 4,911,920 SEP 27,2007
BETOPTIC S Alcon betaxolol hydrochloride 4,911,920 SEP 27,2007
CARDIOLITE Bristol Myers Squibb technetium tc-99m sestamibi kit 4,885,100 SEP 11,2007
COGNEX Sciele Pharma Inc tacrine hydrochloride 4,816,456 SEP 09,2007
COREG Smithkline Beecham carvedilol 4,503,067 SEP 05,2007
COREG CR Sb Pharmco carvedilol phosphate 4,503,067 SEP 05,2007
MIRALUMA Bristol Myers Squibb technetium tc-99m sestamibi kit 4,885,100 SEP 11,2007
NEXIUM Astrazeneca esomeprazole magnesium 4,738,974 SEP 01,2007
PENLAC Sanofi Aventis Us ciclopirox 4,957,730 SEP 18,2007
PULMICORT Astrazeneca budesonide 4,907,583 SEP 13,2007
TECZEM Biovail diltiazem malate; enalapril maleate 4,880,631 SEP 24,2007
TIAMATE Merck diltiazem malate 4,880,631 SEP 24,2007

Courtesy of